-
Product Insights
NewNet Present Value Model: Ikena Oncology Inc’s IK-595
Empower your strategies with our Net Present Value Model: Ikena Oncology Inc's IK-595 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-595 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IK-595 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IK-595 in Solid Tumor Drug Details: IK-595 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IKS-03 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IKS-03 in Follicular Lymphoma Drug Details: IKS-03 (LCB-73, NI-2201) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IKS-03 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IKS-03 in Mantle Cell Lymphoma Drug Details: IKS-03 (LCB-73, NI-2201)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IKS-03 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IKS-03 in Diffuse Large B-Cell Lymphoma Drug Details: IKS-03...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IKS-03 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IKS-03 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IKS-03 in B-Cell Non-Hodgkin Lymphoma Drug Details: IKS-03 (LCB-73, NI-2201)...
-
Product Insights
IK OC Mine
The IK OC Mine is a coal mine in India. It is currently in operation. Empower your strategies with our IK OC Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: IK-175 (KYN-175) was under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: IK-175 (KYN-175) was under...
-
Product Insights
NewNet Present Value Model: Ikena Oncology Inc’s IK-930
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.